6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of May 2025

Commission File Number: 001-41937

Psyence Biomedical Ltd.

(Translation of registrant’s name into English)

121 Richmond Street WestPenthouse Suite 1300Toronto, Ontario M5H 2K1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

X Form 20-F ☐ Form 40-F

EXHIBIT INDEX

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 6, 2025

Exhibit 99.1

Psyence BioMed Announces Effective Date for1-for-7.97 Reverse Stock Split

NEWYORK, May 1, 2025 — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company’s issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a share consolidation at a ratio of up to 1-for-50. Following this approval, the Company’s Board of Directors authorized a 1-for-7.97 consolidation ratio, which will be implemented as the final share structure.

The Company’s common shares are expected to begin trading on a post-consolidated basis at the opening of the market on Monday, May 5, 2025. Following the consolidation, the Company’s common shares will continue to trade under the symbol “PBM” on the Nasdaq Capital Market, with a new CUSIP number 74449F308.

The consolidation is part of the Company’s plan to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) (the “Nasdaq Rule 5450”) for continued listing on The Nasdaq Capital Market.

At the effective time of the consolidation, every 7.97 issued and outstanding shares of the Company will automatically be combined into one issued and outstanding common share. The number of shares and the exercise price of the Company’s outstanding warrants and other equity instruments will also be adjusted proportionately in accordance with their respective terms. As of May 1, 2025, the Company had 4,648,610 common shares issued and outstanding. As a result of the consolidation, the Company will have approximately 583,263 common shares issued and outstanding.

No fractional shares will be issued in connection with the consolidation. Any fractional share resulting from the consolidation will be rounded down to the nearest whole share. The consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company, except for minor adjustments resulting from the treatment of fractional shares. The share consolidation occurs at the registered shareholder level. Shareholders who hold their common shares through brokers, banks, or other nominees (i.e., in 'street name') are considered beneficial holders and may experience a delay in the reflection of the consolidation in their accounts, depending on the procedures of their broker, bank, or nominee.

Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the consolidation. Shareholders holding their shares in book-entry form or through brokerage accounts are not required to take any action. Beneficial holders are encouraged to contact their broker, bank, or custodian with any questions regarding the effect of the share consolidation.

About Psyence BioMed:

Psyence BioMed aims to be one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd.

Email: [email protected]

Media Inquiries: [email protected]

General Information: [email protected]

Phone: +1 416-477-1708

Investor Contact:

Michael Kydd

Investor Relations Advisor

[email protected]

Forward-Looking Statements

This communication contains “forward-lookingstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may relate to future financialand operating results, plans, objectives, expectations, and intentions regarding future operations, products, services, and other matters.Words such as “expects,” “will,” “intends,” “believes,” “plans,” “anticipates,”“projects,” “targets,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this communicationinclude statements regarding the timing and implementation of the share consolidation, the continued listing of the Company’s securitieson Nasdaq, and the anticipated impact of the consolidation. These statements are based on current assumptions and expectations, includingthat the share consolidation will be completed without delay, and that the Company will continue to meet Nasdaq’s ongoing listingstandards.

There are numerous risks and uncertaintiesthat may cause actual results or performance to differ materially from those expressed or implied in these forward-looking statements,including, but not limited to: (i) delays or challenges in completing the share consolidation; (ii) the Company’s ability to maintaincompliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price following theconsolidation; (iv) changes in the regulatory, competitive, and economic landscape; and (v) risks associated with the Company’sdevelopment plans and clinical trials.

These and other important risks and uncertaintiesare described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-284444), filed with theU.S. Securities and Exchange Commission on January 24, 2025, and in other documents filed by the Company from time to time with the SEC.Actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to placeundue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomeddoes not undertake any obligation to update or revise forward-looking statements.

The Company does not make any medical, treatment,or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada, or similar regulatorybodies have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic or nutraceutical products. The efficacyof such products has not been confirmed by authorized clinical research. There is no assurance that the use of such compounds can diagnose,treat, cure, or prevent any disease or condition. Clinical trials and regulatory approvals are required and, if not obtained, may havea material adverse impact on the Company’s business.